Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Eric Lawrence Eisenhauer, M.D.

Title
Institution
Department
Address
Phone

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Jagannathan JP, Steiner A, Bay C, Eisenhauer E, Muto MG, George S, Fennessy FM. Differentiating leiomyosarcoma from leiomyoma: in support of an MR imaging predictive scoring system. Abdom Radiol (NY). 2021 Jun 01. PMID: 34075468.
    Citations:    Fields:    
  2. Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, Chen LM, Cristea M, DeRosa M, Eisenhauer EL, Gershenson DM, Gray HJ, Grisham R, Hakam A, Jain A, Karam A, Konecny GE, Leath CA, Liu J, Mahdi H, Martin L, Matei D, McHale M, McLean K, Miller DS, O'Malley DM, Percac-Lima S, Ratner E, Remmenga SW, Vargas R, Werner TL, Zsiros E, Burns JL, Engh AM. Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021 02 02; 19(2):191-226. PMID: 33545690.
    Citations: 1     Fields:    
  3. Alimena S, Sullivan MW, Philp L, Dorney K, Hubbell H, Del Carmen MG, Goodman A, Bregar A, Growdon WB, Eisenhauer EL, Sisodia RC. Patient reported outcome measures among patients with vulvar cancer at various stages of treatment, recurrence, and survivorship. Gynecol Oncol. 2021 01; 160(1):252-259. PMID: 33139040.
    Citations: 1     Fields:    
  4. Tewari KS, Sill MW, Monk BJ, Penson RT, Moore DH, Lankes HA, Ramondetta LM, Landrum LM, Randall LM, Oaknin A, Leitao MM, Eisenhauer EL, DiSilvestro P, Van Le L, Pearl ML, Burke JJ, Salani R, Richardson DL, Michael HE, Kindelberger DW, Birrer MJ. Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology-Gynecologic Oncology Group Study 240 (NCT 00803062). Mol Cancer Ther. 2020 Aug 26. PMID: 32847980.
    Citations: 1     Fields:    
  5. Alimena S, Scarpetti L, Blouch EL, Rodgers L, Shannon K, Del Carmen M, Goodman A, Growdon WB, Eisenhauer E, Sisodia RC. Factors associated with referral and completion of genetic counseling in women with epithelial ovarian cancer. Int J Gynecol Cancer. 2020 09; 30(9):1397-1403. PMID: 32447294.
    Citations:    Fields:    
  6. Safavi KC, Ricciardi R, Heng M, Eisenhauer EL, Sheer D, Thompson RW, Del Carmen MG. A Different Kind of Perioperative Surgical Home: Hospital at Home After Surgery. Ann Surg. 2020 02; 271(2):227-229. PMID: 31318791.
    Citations:    Fields:    Translation:Humans
  7. Al-Alem LF, Baker AT, Pandya UM, Eisenhauer EL, Rueda BR. Understanding and Targeting Apoptotic Pathways in Ovarian Cancer. Cancers (Basel). 2019 Oct 24; 11(11). PMID: 31652965.
    Citations: 3     
  8. Bercow AS, Eisenhauer EL. Screening and surgical prophylaxis for hereditary cancer syndromes with high risk of endometrial and ovarian cancer. J Surg Oncol. 2019 Oct; 120(5):864-872. PMID: 31355450.
    Citations: 2     Fields:    Translation:Humans
  9. Eisenhauer EL, Chi DS. Ovarian Cancer Surgery - Heed This LION's Roar. N Engl J Med. 2019 02 28; 380(9):871-873. PMID: 30811915.
    Citations: 4     Fields:    Translation:Humans
  10. Hanna TP, Nguyen P, Baetz T, Booth CM, Eisenhauer E. A Population-based Study of Survival Impact of New Targeted and Immune-based Therapies for Metastatic or Unresectable Melanoma. Clin Oncol (R Coll Radiol). 2018 10; 30(10):609-617. PMID: 30196844.
    Citations: 5     Fields:    Translation:Humans
  11. Seamon LG, Java JJ, Monk BJ, Penson RT, Brown J, Mannel RS, Oaknin A, Leitao MM, Eisenhauer EL, Long HJ, Liao SY, Tewari KS. Impact of tumour histology on survival in advanced cervical carcinoma: an NRG Oncology/Gynaecologic Oncology Group Study. Br J Cancer. 2018 01; 118(2):162-170. PMID: 29182608.
    Citations: 2     Fields:    Translation:Humans
  12. Crafton SM, Lynch CD, Cohn DE, Eisenhauer EL. Reproductive counseling, contraception, and unplanned pregnancy in fertile women treated by gynecologic oncologists. Gynecol Oncol Rep. 2017 Feb; 19:22-26. PMID: 28018956.
    Citations:    
  13. Atri M, Zhang Z, Dehdashti F, Lee SI, Ali S, Marques H, Koh WJ, Moore K, Landrum L, Kim JW, DiSilvestro P, Eisenhauer E, Schnell F, Gold M. Utility of PET-CT to evaluate retroperitoneal lymph node metastasis in advanced cervical cancer: Results of ACRIN6671/GOG0233 trial. Gynecol Oncol. 2016 Sep; 142(3):413-9. PMID: 27178725.
    Citations: 15     Fields:    Translation:HumansCTClinical Trials
  14. Cowan RA, Black DR, Hoang LN, Park KJ, Soslow RA, Backes FJ, Gardner GJ, Abu-Rustum NR, Leitao MM, Eisenhauer EL, Chi DS. A pilot study of topical imiquimod therapy for the treatment of recurrent extramammary Paget's disease. Gynecol Oncol. 2016 Jul; 142(1):139-143. PMID: 27112632.
    Citations: 9     Fields:    Translation:HumansCTClinical Trials
  15. Cohn DE, Castellon-Larios K, Huffman L, Salani R, Fowler JM, Copeland LJ, O'Malley DM, Backes FJ, Eisenhauer EL, Abdel-Rasoul M, Puente EG, Bergese SD. A Prospective, Comparative Study for the Evaluation of Postoperative Pain and Quality of Recovery in Patients Undergoing Robotic Versus Open Hysterectomy for Staging of Endometrial Cancer. J Minim Invasive Gynecol. 2016 Mar-Apr; 23(3):429-34. PMID: 26776677.
    Citations: 2     Fields:    Translation:Humans
  16. Crafton S, Nekkanti S, Lynch C, Cohn DE, Fowler JM, Copeland LJ, O'Malley DM, Salani R, Backes FJ, Eisenhauer EL. Documentation of Pregnancy Risk Assessment and Pregnancy Among Women Presenting for Gynecologic Oncology Consultation. Int J Gynecol Cancer. 2016 Jan; 26(1):35-42. PMID: 26658364.
    Citations: 1     Fields:    Translation:Humans
  17. Eskander RN, Ali S, Dellinger T, Lankes HA, Randall LM, Ramirez NC, Monk BJ, Walker JL, Eisenhauer E, Hoang BH. Expression Patterns of the Wnt Pathway Inhibitors Dickkopf3 and Secreted Frizzled-Related Proteins 1 and 4 in Endometrial Endometrioid Adenocarcinoma: An NRG Oncology/Gynecologic Oncology Group Study. Int J Gynecol Cancer. 2016 Jan; 26(1):125-32. PMID: 26397159.
    Citations: 5     Fields:    Translation:HumansCells
  18. Jackson AL, Eisenhauer EL, Herzog TJ. Emerging therapies: angiogenesis inhibitors for ovarian cancer. Expert Opin Emerg Drugs. 2015 Jun; 20(2):331-46. PMID: 26001052.
    Citations: 10     Fields:    Translation:HumansAnimals
  19. Liang MI, Rosen MA, Rath KS, Hade EM, Clements AE, Backes FJ, Eisenhauer EL, Salani R, O'Malley DM, Fowler JM, Cohn DE. Predicting inpatient stay lasting 2 midnights or longer after robotic surgery for endometrial cancer. J Minim Invasive Gynecol. 2015 May-Jun; 22(4):583-9. PMID: 25573182.
    Citations:    Fields:    Translation:Humans
  20. McCann GA, Eisenhauer EL. Hereditary cancer syndromes with high risk of endometrial and ovarian cancer: surgical options for personalized care. J Surg Oncol. 2015 Jan; 111(1):118-24. PMID: 25139656.
    Citations: 5     Fields:    Translation:Humans
  21. Backes FJ, Billingsley CC, Martin DD, Tierney BJ, Eisenhauer EL, Cohn DE, O'Malley DM, Salani R, Copeland LJ, Fowler JM. Does intra-operative radiation at the time of pelvic exenteration improve survival for patients with recurrent, previously irradiated cervical, vaginal, or vulvar cancer? Gynecol Oncol. 2014 Oct; 135(1):95-9. PMID: 25084510.
    Citations: 8     Fields:    Translation:Humans
  22. Eisenhauer EL, Zanagnolo V, Cohn DE, Salani R, O'Malley DM, Sutton G, Callahan MJ, Cobb B, Fowler JM, Copeland LJ. A phase II study of gemcitabine, carboplatin and bevacizumab for the treatment of platinum-sensitive recurrent ovarian cancer. Gynecol Oncol. 2014 Aug; 134(2):262-6. PMID: 24910452.
    Citations: 5     Fields:    Translation:HumansCTClinical Trials
  23. Salani R, O'Malley DM, Copeland LJ, Cohn DE, Backes FJ, Fowler JM, Eisenhauer EL. Feasibility of interval cytoreduction following neoadjuvant chemotherapy with carboplatin, weekly paclitaxel, and bevacizumab for advanced ovarian cancer--a phase 1 study. Int J Gynecol Cancer. 2014 May; 24(4):682-6. PMID: 24651631.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  24. Sandadi S, Long K, Andikyan V, Vernon J, Zivanovic O, Eisenhauer EL, Levine DA, Sonoda Y, Barakat RR, Chi DS. Postoperative outcomes among patients undergoing thoracostomy tube placement at time of diaphragm peritonectomy or resection during primary cytoreductive surgery for ovarian cancer. Gynecol Oncol. 2014 Feb; 132(2):299-302. PMID: 24296344.
    Citations: 3     Fields:    Translation:Humans
  25. Zhao R, Han C, Eisenhauer E, Kroger J, Zhao W, Yu J, Selvendiran K, Liu X, Wani AA, Wang QE. DNA damage-binding complex recruits HDAC1 to repress Bcl-2 transcription in human ovarian cancer cells. Mol Cancer Res. 2014 Mar; 12(3):370-80. PMID: 24249678.
    Citations: 12     Fields:    Translation:HumansCells
  26. Liang MI, Rosen MA, Rath KS, Clements AE, Backes FJ, Eisenhauer EL, Salani R, O'Malley DM, Fowler JM, Cohn DE. Reducing readmissions after robotic surgical management of endometrial cancer: a potential for improved quality care. Gynecol Oncol. 2013 Dec; 131(3):508-11. PMID: 24096114.
    Citations: 4     Fields:    Translation:Humans
  27. Ricci S, Giuntoli RL, Eisenhauer E, Lopez MA, Krill L, Tanner EJ, Gehrig PA, Havrilesky LJ, Secord AA, Levinson K, Frasure H, Celano P, Fader AN. Does adjuvant chemotherapy improve survival for women with early-stage uterine leiomyosarcoma? Gynecol Oncol. 2013 Dec; 131(3):629-33. PMID: 24016408.
    Citations: 10     Fields:    Translation:Humans
  28. Backes FJ, Richardson DL, McCann GA, Smith B, Salani R, Eisenhauer EL, Fowler JM, Copeland LJ, Cohn DE, O'Malley DM. Should bevacizumab be continued after progression on bevacizumab in recurrent ovarian cancer? Int J Gynecol Cancer. 2013 Jun; 23(5):833-8. PMID: 23640292.
    Citations: 5     Fields:    Translation:Humans
  29. Zighelboim I, Wright JD, Gao F, Case AS, Massad LS, Mutch DG, Powell MA, Thaker PH, Eisenhauer EL, Cohn DE, Valea FA, Alvarez Secord A, Lippmann LT, Dehdashti F, Rader JS. Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer. Gynecol Oncol. 2013 Jul; 130(1):64-8. PMID: 23591400.
    Citations: 21     Fields:    Translation:HumansCTClinical Trials
  30. Rath KS, Loseth D, Muscarella P, Phillips GS, Fowler JM, O'Malley DM, Cohn DE, Copeland LJ, Eisenhauer EL, Salani R. Outcomes following percutaneous upper gastrointestinal decompressive tube placement for malignant bowel obstruction in ovarian cancer. Gynecol Oncol. 2013 Apr; 129(1):103-6. PMID: 23369942.
    Citations: 4     Fields:    Translation:Humans
  31. McCann GA, Boutsicaris CE, Preston MM, Backes FJ, Eisenhauer EL, Fowler JM, Cohn DE, Copeland LJ, Salani R, O'Malley DM. Neuroendocrine carcinoma of the uterine cervix: the role of multimodality therapy in early-stage disease. Gynecol Oncol. 2013 Apr; 129(1):135-9. PMID: 23357610.
    Citations: 13     Fields:    Translation:Humans
  32. McCann GA, Taege SK, Boutsicaris CE, Phillips GS, Eisenhauer EL, Fowler JM, O'Malley DM, Copeland LJ, Cohn DE, Salani R. The impact of close surgical margins after radical hysterectomy for early-stage cervical cancer. Gynecol Oncol. 2013 Jan; 128(1):44-48. PMID: 23138134.
    Citations: 10     Fields:    Translation:Humans
  33. Backes FJ, Tierney BJ, Eisenhauer EL, Bahnson RR, Cohn DE, Fowler JM. Complications after double-barreled wet colostomy compared to separate urinary and fecal diversion during pelvic exenteration: time to change back? Gynecol Oncol. 2013 Jan; 128(1):60-64. PMID: 22892363.
    Citations: 4     Fields:    Translation:Humans
  34. McCann GA, Smith B, Backes FJ, Rath K, Chacko S, Salani R, Eisenhauer E, Fowler JM, Cohn DE, O'Malley DM. Recurrent ovarian cancer: is there a role for re-treatment with bevacizumab after an initial complete response to a bevacizumab-containing regimen? Gynecol Oncol. 2012 Nov; 127(2):362-6. PMID: 22885866.
    Citations: 4     Fields:    Translation:Humans
  35. Tierney BJ, McCann GA, Cohn DE, Eisenhauer E, Sudhakar M, Kuppusamy P, Hideg K, Selvendiran K. HO-3867, a STAT3 inhibitor induces apoptosis by inactivation of STAT3 activity in BRCA1-mutated ovarian cancer cells. . 2012 Jul; 13(9):766-75. PMID: 22801507.
    Citations: 14     Translation:HumansCells
  36. Lindemann K, Christensen RD, Vergote I, Stuart G, Izquierdo MA, Kærn J, Havsteen H, Eisenhauer E, Ridderheim M, Lopez AB, Hirte H, Aavall-Lundquvist E, Vrdoljak E, Green J, Kristensen GB. First-line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin (TEC versus TC)--a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG. Ann Oncol. 2012 Oct; 23(10):2613-2619. PMID: 22539562.
    Citations: 8     Fields:    Translation:HumansCTClinical Trials
  37. Brundage M, Gropp M, Mefti F, Mann K, Lund B, Gebski V, Wolfram G, Reed N, Pignata S, Ferrero A, Brown C, Eisenhauer E, Pujade-Lauraine E. Health-related quality of life in recurrent platinum-sensitive ovarian cancer--results from the CALYPSO trial. Ann Oncol. 2012 Aug; 23(8):2020-2027. PMID: 22291207.
    Citations: 12     Fields:    Translation:HumansCTClinical Trials
  38. Nagel CI, Backes FJ, Hade EM, Cohn DE, Eisenhauer EL, O'Malley DM, Fowler JM, Copeland LJ, Salani R. Effect of chemotherapy delays and dose reductions on progression free and overall survival in the treatment of epithelial ovarian cancer. Gynecol Oncol. 2012 Feb; 124(2):221-4. PMID: 22055764.
    Citations: 11     Fields:    Translation:Humans
  39. Dizon DS, Sill MW, Gould N, Rubin SC, Yamada SD, Debernardo RL, Mannel RS, Eisenhauer EL, Duska LR, Fracasso PM. Phase I feasibility study of intraperitoneal cisplatin and intravenous paclitaxel followed by intraperitoneal paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: a gynecologic oncology group study. Gynecol Oncol. 2011 Nov; 123(2):182-6. PMID: 21820161.
    Citations: 6     Fields:    Translation:HumansCTClinical Trials
  40. O'Malley DM, Richardson DL, Rheaume PS, Salani R, Eisenhauer EL, McCann GA, Fowler JM, Copeland LJ, Cohn DE, Backes FJ. Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer. Gynecol Oncol. 2011 May 01; 121(2):269-72. PMID: 21315428.
    Citations: 20     Fields:    Translation:Humans
  41. Aletti GD, Eisenhauer EL, Santillan A, Axtell A, Aletti G, Holschneider C, Chi DS, Bristow RE, Cliby WA. Identification of patient groups at highest risk from traditional approach to ovarian cancer treatment. Gynecol Oncol. 2011 Jan; 120(1):23-8. PMID: 20933255.
    Citations: 51     Fields:    Translation:Humans
  42. Tanner EJ, Chi DS, Eisenhauer EL, Diaz-Montes TP, Santillan A, Bristow RE. Surveillance for the detection of recurrent ovarian cancer: survival impact or lead-time bias? Gynecol Oncol. 2010 May; 117(2):336-40. PMID: 20153027.
    Citations: 19     Fields:    Translation:Humans
  43. Hurt JD, Richardson DL, Seamon LG, Fowler JF, Copeland LJ, Cohn DE, Eisenhauer E, Salani R, O'Malley DM. Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer. Gynecol Oncol. 2009 Dec; 115(3):396-400. PMID: 19804901.
    Citations: 14     Fields:    Translation:Humans
  44. Chi DS, Eisenhauer EL, Zivanovic O, Sonoda Y, Abu-Rustum NR, Levine DA, Guile MW, Bristow RE, Aghajanian C, Barakat RR. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol. 2009 Jul; 114(1):26-31. PMID: 19395008.
    Citations: 116     Fields:    Translation:Humans
  45. Chi DS, Zivanovic O, Palayekar MJ, Eisenhauer EL, Abu-Rustum NR, Sonoda Y, Levine DA, Leitao MM, Brown CL, Barakat RR. A contemporary analysis of the ability of preoperative serum CA-125 to predict primary cytoreductive outcome in patients with advanced ovarian, tubal and peritoneal carcinoma. Gynecol Oncol. 2009 Jan; 112(1):6-10. PMID: 19100916.
    Citations: 21     Fields:    Translation:Humans
  46. Kehoe SM, Eisenhauer EL, Abu-Rustum NR, Sonoda Y, D'Angelica M, Jarnagin WR, Barakat RR, Chi DS. Incidence and management of pancreatic leaks after splenectomy with distal pancreatectomy performed during primary cytoreductive surgery for advanced ovarian, peritoneal and fallopian tube cancer. Gynecol Oncol. 2009 Mar; 112(3):496-500. PMID: 19091388.
    Citations: 6     Fields:    Translation:Humans
  47. Kehoe SM, Eisenhauer EL, Chi DS. Upper abdominal surgical procedures: liver mobilization and diaphragm peritonectomy/resection, splenectomy, and distal pancreatectomy. Gynecol Oncol. 2008 Nov; 111(2 Suppl):S51-5. PMID: 18801559.
    Citations: 8     Fields:    Translation:Humans
  48. Eisenhauer EL, Sonoda Y, Levine DA, Abu-Rustum NR, Gemignani ML, Sabbatini PJ, Barakat RR, Chi DS. Platinum resistance and impaired survival in patients with advanced primary peritoneal carcinoma: matched-case comparison with patients with epithelial ovarian carcinoma. Am J Obstet Gynecol. 2008 Feb; 198(2):213.e1-7. PMID: 18226627.
    Citations: 6     Fields:    Translation:Humans
  49. Eisenhauer EL, Abu-Rustum NR, Sonoda Y, Aghajanian C, Barakat RR, Chi DS. The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer. Gynecol Oncol. 2008 Feb; 108(2):276-81. PMID: 18063020.
    Citations: 28     Fields:    Translation:Humans
  50. Zivanovic O, Eisenhauer EL, Zhou Q, Iasonos A, Sabbatini P, Sonoda Y, Abu-Rustum NR, Barakat RR, Chi DS. The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancer. Gynecol Oncol. 2008 Feb; 108(2):287-92. PMID: 17996927.
    Citations: 23     Fields:    Translation:Humans
  51. Chi DS, Ramirez PT, Teitcher JB, Mironov S, Sarasohn DM, Iyer RB, Eisenhauer EL, Abu-Rustum NR, Sonoda Y, Levine DA, Brown CL, Aghajanian C, Gershenson DM, Hoskins WJ, Hricak H, Barakat RR. Prospective study of the correlation between postoperative computed tomography scan and primary surgeon assessment in patients with advanced ovarian, tubal, and peritoneal carcinoma reported to have undergone primary surgical cytoreduction to residual disease 1 cm or less. J Clin Oncol. 2007 Nov 01; 25(31):4946-51. PMID: 17971592.
    Citations: 10     Fields:    Translation:HumansCTClinical Trials
  52. Chi DS, Palayekar MJ, Sonoda Y, Abu-Rustum NR, Awtrey CS, Huh J, Eisenhauer EL, Barakat RR, Kattan MW. Nomogram for survival after primary surgery for bulky stage IIIC ovarian carcinoma. Gynecol Oncol. 2008 Jan; 108(1):191-4. PMID: 17950784.
    Citations: 18     Fields:    Translation:Humans
  53. Aletti GD, Santillan A, Eisenhauer EL, Hu J, Aletti G, Podratz KC, Bristow RE, Chi DS, Cliby WA. A new frontier for quality of care in gynecologic oncology surgery: multi-institutional assessment of short-term outcomes for ovarian cancer using a risk-adjusted model. Gynecol Oncol. 2007 Oct; 107(1):99-106. PMID: 17602726.
    Citations: 32     Fields:    Translation:Humans
  54. Eisenhauer EL, Wypych KA, Mehrara BJ, Lawson C, Chi DS, Barakat RR, Abu-Rustum NR. Comparing surgical outcomes in obese women undergoing laparotomy, laparoscopy, or laparotomy with panniculectomy for the staging of uterine malignancy. Ann Surg Oncol. 2007 Aug; 14(8):2384-91. PMID: 17522943.
    Citations: 12     Fields:    Translation:Humans
  55. Eisenhauer EL, Tew WP, Levine DA, Lichtman SM, Brown CL, Aghajanian C, Huh J, Barakat RR, Chi DS. Response and outcomes in elderly patients with stages IIIC-IV ovarian cancer receiving platinum-taxane chemotherapy. Gynecol Oncol. 2007 Aug; 106(2):381-7. PMID: 17509673.
    Citations: 19     Fields:    Translation:Humans
  56. Bristow RE, Eisenhauer EL, Santillan A, Chi DS. Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction. Gynecol Oncol. 2007 Feb; 104(2):480-90. PMID: 17166564.
    Citations: 31     Fields:    Translation:Humans
  57. Eisenhauer EL, Chi DS. Liver mobilization and diaphragm peritonectomy/resection. Gynecol Oncol. 2007 Feb; 104(2 Suppl 1):25-8. PMID: 17166568.
    Citations: 5     Fields:    Translation:Humans
  58. Knowling M, Blackstein M, Tozer R, Bramwell V, Dancey J, Dore N, Matthews S, Eisenhauer E. A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: A National Cancer Institute of Canada Clinical Trials Group trial. Invest New Drugs. 2006 Sep; 24(5):435-9. PMID: 16528479.
    Citations: 26     Fields:    Translation:HumansCTClinical Trials
  59. Eisenhauer EL, Abu-Rustum NR, Sonoda Y, Levine DA, Poynor EA, Aghajanian C, Jarnagin WR, DeMatteo RP, D'Angelica MI, Barakat RR, Chi DS. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. Gynecol Oncol. 2006 Dec; 103(3):1083-90. PMID: 16890277.
    Citations: 58     Fields:    Translation:Humans
  60. Eisenhauer EL, D'Angelica MI, Abu-Rustum NR, Sonoda Y, Jarnagin WR, Barakat RR, Chi DS. Incidence and management of pleural effusions after diaphragm peritonectomy or resection for advanced mullerian cancer. Gynecol Oncol. 2006 Dec; 103(3):871-7. PMID: 16815536.
    Citations: 13     Fields:    Translation:Humans
  61. Wong RP, Baetz T, Krahn MJ, Biagi J, Wainman N, Eisenhauer E. SarCNU in recurrent or metastatic colorectal cancer: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. Invest New Drugs. 2006 Jul; 24(4):347-51. PMID: 16502354.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  62. Chi DS, Eisenhauer EL, Lang J, Huh J, Haddad L, Abu-Rustum NR, Sonoda Y, Levine DA, Hensley M, Barakat RR. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol. 2006 Nov; 103(2):559-64. PMID: 16714056.
    Citations: 127     Fields:    Translation:HumansCells
  63. Trudeau ME, Crump M, Charpentier D, Yelle L, Bordeleau L, Matthews S, Eisenhauer E. Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada - Clinical Trials Group (NCIC-CTG). Ann Oncol. 2006 Jun; 17(6):952-6. PMID: 16565212.
    Citations: 30     Fields:    Translation:HumansCTClinical Trials
  64. McCreath WA, Eisenhauer EL, Abu-Rustum NR, Venkatraman ES, Caceres A, Bier R, Huh J, Cho J, Barakat RR, Chi DS. Identification of prognostic factors after positive second-look surgery in epithelial ovarian carcinoma. Gynecol Oncol. 2006 Jul; 102(1):8-14. PMID: 16427689.
    Citations:    Fields:    Translation:HumansCells
  65. Pfisterer J, Vergote I, Du Bois A, Eisenhauer E. Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer. Int J Gynecol Cancer. 2005 May-Jun; 15 Suppl 1:36-41. PMID: 15839957.
    Citations: 20     Fields:    Translation:HumansCTClinical Trials
  66. Stuart G, Avall-Lundqvist E, du Bois A, Bookman M, Bowtell D, Brady M, Casado A, Cervantes A, Eisenhauer E, Friedlaender M, Fujiwara K, Grenman S, Guastalla JP, Harper P, Hogberg T, Kaye S, Kitchener H, Kristensen G, Mannel R, Meier W, Miller B, Oza A, Ozols R, Parmar M, Pfisterer J, Poveda A, Provencher D, Pujade-Lauraine E, Quinn M, Randall M, Rochon J, Rustin G, Sagae S, Stehman F, Trimble E, Thigpen T, Vasey P, Vergote I, Verheijen R, Vermorken J, Wagner U. 3rd International Ovarian Cancer Consensus Conference: outstanding issues for future consideration. Ann Oncol. 2005; 16 Suppl 8:viii36-viii38. PMID: 16239235.
    Citations: 3     Fields:    Translation:Humans
  67. du Bois A, Quinn M, Thigpen T, Vermorken J, Avall-Lundqvist E, Bookman M, Bowtell D, Brady M, Casado A, Cervantes A, Eisenhauer E, Friedlaender M, Fujiwara K, Grenman S, Guastalla JP, Harper P, Hogberg T, Kaye S, Kitchener H, Kristensen G, Mannel R, Meier W, Miller B, Neijt JP, Oza A, Ozols R, Parmar M, Pecorelli S, Pfisterer J, Poveda A, Provencher D, Pujade-Lauraine E, Randall M, Rochon J, Rustin G, Sagae S, Stehman F, Stuart G, Trimble E, Vasey P, Vergote I, Verheijen R, Wagner U. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol. 2005; 16 Suppl 8:viii7-viii12. PMID: 16239238.
    Citations: 98     Fields:    Translation:Humans
  68. Gelmon K, Hirte H, Fisher B, Walsh W, Ptaszynski M, Hamilton M, Onetto N, Eisenhauer E. A phase 1 study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every three weeks in patients with solid cancers. Invest New Drugs. 2004 Aug; 22(3):263-75. PMID: 15122073.
    Citations: 5     Fields:    Translation:HumansCTClinical Trials
  69. Ma BB, Oza A, Eisenhauer E, Stanimir G, Carey M, Chapman W, Latta E, Sidhu K, Powers J, Walsh W, Fyles A. The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers--a study of the National Cancer Institute of Canada Clinical Trials Group. Int J Gynecol Cancer. 2004 Jul-Aug; 14(4):650-8. PMID: 15304161.
    Citations: 28     Fields:    Translation:HumansCTClinical Trials
  70. MacKenzie MJ, Hirte HW, Siu LL, Gelmon K, Ptaszynski M, Fisher B, Eisenhauer E. A phase I study of OSI-211 and cisplatin as intravenous infusions given on days 1, 2 and 3 every 3 weeks in patients with solid cancers. Ann Oncol. 2004 Apr; 15(4):665-70. PMID: 15033677.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  71. Kristensen GB, Vergote I, Stuart G, Del Campo JM, Kaern J, Lopez AB, Eisenhauer E, Aavall-Lundquist E, Ridderheim M, Havsteen H, Mirza MR, Scheistroen M, Vrdoljak E. First-line treatment of ovarian cancer FIGO stages IIb-IV with paclitaxel/epirubicin/carboplatin versus paclitaxel/carboplatin. Int J Gynecol Cancer. 2003 Nov-Dec; 13 Suppl 2:172-7. PMID: 14656276.
    Citations: 10     Fields:    Translation:HumansCTClinical Trials
  72. Oza AM, Elit L, Swenerton K, Faught W, Ghatage P, Carey M, McIntosh L, Dorr A, Holmlund JT, Eisenhauer E. Phase II study of CGP 69846A (ISIS 5132) in recurrent epithelial ovarian cancer: an NCIC clinical trials group study (NCIC IND.116). Gynecol Oncol. 2003 Apr; 89(1):129-33. PMID: 12694666.
    Citations: 9     Fields:    Translation:HumansCTClinical Trials
  73. Shepherd FA, Dancey J, Arnold A, Neville A, Rusthoven J, Johnson RD, Fisher B, Eisenhauer E. Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group. Cancer. 2001 Aug 01; 92(3):595-600. PMID: 11505404.
    Citations: 21     Fields:    Translation:HumansCTClinical Trials
  74. Dent S, Zee B, Dancey J, Hanauske A, Wanders J, Eisenhauer E. Application of a new multinomial phase II stopping rule using response and early progression. J Clin Oncol. 2001 Feb 01; 19(3):785-91. PMID: 11157032.
    Citations: 19     Fields:    Translation:Humans
  75. Eisenhauer E, Dancey J. Impact of new non-cytotoxics in the treatment of ovarian cancer. Int J Gynecol Cancer. 2001; 11 Suppl 1:68-72. PMID: 11489007.
    Citations: 1     Fields:    Translation:HumansCells
  76. Hoskins P, Eisenhauer E, Vergote I, Dubuc-Lissoir J, Fisher B, Grimshaw R, Oza A, Plante M, Stuart G, Vermorken J. Phase II feasibility study of sequential couplets of Cisplatin/Topotecan followed by paclitaxel/cisplatin as primary treatment for advanced epithelial ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group Study. J Clin Oncol. 2000 Dec 15; 18(24):4038-44. PMID: 11118464.
    Citations: 13     Fields:    Translation:HumansCTClinical Trials
  77. Gelmon KA, Latreille J, Tolcher A, Génier L, Fisher B, Forand D, D'Aloisio S, Vernillet L, Daigneault L, Lebecq A, Besenval M, Eisenhauer E. Phase I dose-finding study of a new taxane, RPR 109881A, administered as a one-hour intravenous infusion days 1 and 8 to patients with advanced solid tumors. J Clin Oncol. 2000 Dec 15; 18(24):4098-108. PMID: 11118471.
    Citations: 9     Fields:    Translation:HumansCTClinical Trials
  78. Flinn IW, Kopecky KJ, Foucar MK, Head D, Bennett JM, Hutchison R, Corbett W, Cassileth P, Habermann T, Golomb H, Rai K, Eisenhauer E, Appelbaum F, Cheson B, Grever MR. Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood. 2000 Nov 01; 96(9):2981-6. PMID: 11049974.
    Citations: 32     Fields:    Translation:HumansCTClinical Trials
  79. Miller WH, Reyno LM, Loewen GR, Huan S, Winquist E, Moore M, Cato A, Jaunakais D, Truglia JA, Matthews S, Dancey J, Eisenhauer E. A phase I-II study of 9-cis retinoic acid and interferon-alpha2b in patients with advanced renal-cell carcinoma: an NCIC Clinical Trials Group study. Ann Oncol. 2000 Nov; 11(11):1387-9. PMID: 11142476.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  80. Geels P, Eisenhauer E, Bezjak A, Zee B, Day A. Palliative effect of chemotherapy: objective tumor response is associated with symptom improvement in patients with metastatic breast cancer. J Clin Oncol. 2000 Jun; 18(12):2395-405. PMID: 10856099.
    Citations: 35     Fields:    Translation:HumansCTClinical Trials
  81. Johnston JB, Eisenhauer E, Wainman N, Corbett WE, Zaentz SD, Daeninck PJ. Long-term outcome following treatment of hairy cell leukemia with pentostatin (Nipent): a National Cancer Institute of Canada study. Semin Oncol. 2000 Apr; 27(2 Suppl 5):32-6. PMID: 10877049.
    Citations: 9     Fields:    Translation:HumansCTClinical Trials
  82. Khoo K, Brandes L, Reyno L, Arnold A, Dent S, Vandenberg T, Lebwohl D, Fisher B, Eisenhauer E. Phase II trial of N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine.HCl and doxorubicin chemotherapy in metastatic breast cancer: A National Cancer Institute of Canada clinical trials group study. J Clin Oncol. 1999 Nov; 17(11):3431-7. PMID: 10550138.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  83. Gelmon K, Eisenhauer E, Bryce C, Tolcher A, Mayer L, Tomlinson E, Zee B, Blackstein M, Tomiak E, Yau J, Batist G, Fisher B, Iglesias J. Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer. J Clin Oncol. 1999 Oct; 17(10):3038-47. PMID: 10506598.
    Citations: 21     Fields:    Translation:HumansCTClinical Trials
  84. Rusthoven JJ, Eisenhauer E, Butts C, Gregg R, Dancey J, Fisher B, Iglesias J. Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1999 Apr; 17(4):1194. PMID: 10561178.
    Citations: 21     Fields:    Translation:HumansCTClinical Trials
  85. Kirkbride P, Gelmon K, Eisenhauer E. Paclitaxel and concurrent radiotherapy in locally advanced non-small cell lung cancer: the Canadian experience. Semin Radiat Oncol. 1999 Apr; 9(2 Suppl 1):102-7. PMID: 10210548.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  86. Crump M, Lipton J, Hedley D, Sutton D, Shepherd F, Minden M, Stewart K, Beare S, Eisenhauer E. Phase I trial of sequential topotecan followed by etoposide in adults with myeloid leukemia: a National Cancer Institute of Canada Clinical Trials Group Study. Leukemia. 1999 Mar; 13(3):343-7. PMID: 10086724.
    Citations: 6     Fields:    Translation:HumansCTClinical Trials
  87. Hoskins P, Eisenhauer E, Beare S, Roy M, Drouin P, Stuart G, Bryson P, Grimshaw R, Capstick V, Zee B. Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol. 1998 Jun; 16(6):2233-7. PMID: 9626225.
    Citations: 15     Fields:    Translation:HumansCTClinical Trials
  88. Shepherd FA, Eisenhauer E. Ifosfamide and paclitaxel combinations for the treatment of advanced non-small cell lung cancer. Semin Oncol. 1998 Feb; 25(1 Suppl 2):2-7. PMID: 9535204.
    Citations:    Fields:    Translation:Humans
  89. Kirkbride P, Gelmon K, Eisenhauer E, Fisher B, Dulude H. A phase I/II study of paclitaxel (TAXOL) and concurrent radiotherapy in advanced nonsmall cell lung cancer. Int J Radiat Oncol Biol Phys. 1997 Dec 01; 39(5):1107-11. PMID: 9392551.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  90. Swenerton K, Hoskins P, Stuart G, Batist G, Pike J, Onetto N, Fisher B, Eisenhauer E. A phase I study of bi-weekly paclitaxel/cisplatin as initial therapy for advanced ovarian cancer. A study of the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol. 1996 Dec; 7(10):1077-9. PMID: 9037368.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  91. Shepherd FA, Latreille J, Paul K, Eisenhauer E. Phase I dose-escalation trial of paclitaxel and ifosfamide in patients with advanced non-small cell lung cancer. Semin Oncol. 1996 Dec; 23(6 Suppl 16):84-90. PMID: 9007130.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  92. Shepherd FA, Latreille J, Crump M, Stewart D, Tomiak E, Eisenhauer E, Fisher B. Phase I study of paclitaxel (Taxol) and ifosfamide in previously untreated patients with advanced non-small-cell lung cancer. A study of the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol. 1996 Mar; 7(3):311-3. PMID: 8740797.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  93. Macdonald D, Cairncross G, Stewart D, Forsyth P, Sawka C, Wainman N, Eisenhauer E. Phase II study of topotecan in patients with recurrent malignant glioma. National Clinical Institute of Canada Clinical Trials Group. Ann Oncol. 1996 Feb; 7(2):205-7. PMID: 8777179.
    Citations: 22     Fields:    Translation:HumansCTClinical Trials
  94. Forsyth P, Cairncross G, Stewart D, Goodyear M, Wainman N, Eisenhauer E. Phase II trial of docetaxel in patients with recurrent malignant glioma: a study of the National Cancer Institute of Canada Clinical Trials Group. Invest New Drugs. 1996; 14(2):203-6. PMID: 8913841.
    Citations: 12     Fields:    Translation:HumansCTClinical Trials
  95. Eisenhauer E. Docetaxel: current status and future prospects. J Clin Oncol. 1995 Dec; 13(12):2865-8. PMID: 8523048.
    Citations: 7     Fields:    Translation:Humans
  96. Cormier Y, Eisenhauer E, Muldal A, Gregg R, Ayoub J, Goss G, Stewart D, Tarasoff P, Wong D. Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC). A study of the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol. 1994 Mar; 5(3):283-5. PMID: 8186176.
    Citations: 14     Fields:    Translation:HumansCTClinical Trials
  97. Arnold A, Ayoub J, Douglas L, Hoogendoorn P, Skingley L, Gelmon K, Hirsh V, Eisenhauer E. Phase II trial of 13-cis-retinoic acid plus interferon alpha in non-small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. J Natl Cancer Inst. 1994 Feb 16; 86(4):306-9. PMID: 8158687.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  98. Rusthoven JJ, Eisenhauer E, Mazurka J, Hirte H, O'Connell G, Muldal A, Lu HX, Onetto N, Swenerton K, Jeffrey J. Phase I clinical trial of recombinant human interleukin-3 combined with carboplatin in the treatment of patients with recurrent ovarian carcinoma. J Natl Cancer Inst. 1993 May 19; 85(10):823-5. PMID: 8487328.
    Citations: 2     Fields:    Translation:HumansCellsCTClinical Trials
  99. Maroun JA, Skillings J, MacCormick R, Potvin M, Wielgosz G, Davidson JR, Eisenhauer E. Phase II study on DuP 937 (Teloxantrone) in colorectal carcinoma. A Canadian National Cancer Institute Clinical Trial Group study. Invest New Drugs. 1993 May-Aug; 11(2-3):235-7. PMID: 8262739.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  100. ten Bokkel Huinink WW, Eisenhauer E, Swenerton K. Preliminary evaluation of a multicenter, randomized comparative study of TAXOL (paclitaxel) dose and infusion length in platinum-treated ovarian cancer. Canadian-European Taxol Cooperative Trial Group. Cancer Treat Rev. 1993; 19 Suppl C:79-86. PMID: 8106156.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  101. Rusthoven J, Levin L, Eisenhauer E, Mazurka J, Carmichael J, O'Connell G, Bryson P, Hirte H, Koski B. Two phase I studies of carboplatin dose escalation in chemotherapy-naive ovarian cancer patients supported with granulocyte-macrophage colony-stimulating factor. J Natl Cancer Inst. 1991 Dec 04; 83(23):1748-53. PMID: 1770554.
    Citations: 3     Fields:    Translation:HumansCellsCTClinical Trials
  102. Maroun JA, Stewart DJ, Verma S, Evans WK, Eisenhauer E. Phase I study of acivicin and cisplatin in non-small-cell lung cancer. A National Cancer Institute of Canada study. Am J Clin Oncol. 1990 Oct; 13(5):401-4. PMID: 2171318.
    Citations: 5     Fields:    Translation:Humans
  103. Bramwell V, Quirt I, Warr D, Verma S, Young V, Knowling M, Eisenhauer E. Combination chemotherapy with doxorubicin, dacarbazine, and ifosfamide in advanced adult soft tissue sarcoma. Canadian Sarcoma Group--National Cancer Institute of Canada Clinical Trials Group. J Natl Cancer Inst. 1989 Oct 04; 81(19):1496-9. PMID: 2778839.
    Citations: 6     Fields:    Translation:Humans
  104. Evans WK, Eisenhauer E, Hughes P, Maroun JA, Ayoub J, Shepherd FA, Feld R. VP-16 and carboplatin in previously untreated patients with extensive small cell lung cancer: a study of the National Cancer Institute of Canada Clinical Trials Group. Br J Cancer. 1988 Oct; 58(4):464-8. PMID: 2849976.
    Citations: 5     Fields:    Translation:Humans
  105. Maroun JA, Fields AL, Pater JL, Stewart DJ, Cripps C, Eisenhauer E. Phase II study of acivicin in colorectal carcinoma: a National Cancer Institute of Canada study. Cancer Treat Rep. 1984 Sep; 68(9):1121-3. PMID: 6478451.
    Citations: 3     Fields:    Translation:Humans
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Eisenhauer's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (342)
Explore
_
Co-Authors (21)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.